Skip to main content

Table 1 Inclusion and Exclusion criteria

From: Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

Inclusion criteria Exclusion criteria
18–80 years of age Known hypersensitivity or contraindications to alirocumab and/or statin therapy
Diagnosed as stable coronary artery disease or acute coronary syndrome Received balloon angioplasty or stent implantation for target lesion
Received OCT imaging measurement Unable to conduct OCT imaging analysis
LDL cholesterol values ≥1.81 mmol/L for patients with ACS or ≥ 2.59 mmol/L for non-ACS patients despite statin therapy Prior usage of PCSK9 inhibitors
At least one intermediate lesion (50–70% diameter stenosis) in de novo coronary arteries Severe renal dysfunction (creatinine clearance < 30 mL/min)
Provided written informed consent Severe hepatic dysfunction
Baseline triglyceride > 400 mg/dl
History of hemorrhagic stroke
Pregnant or breast-feeding women
Life expectancy < 1 year
Inappropriate for the study for any reason based on the investigators’ judgement
  1. LDL Low-density lipoprotein, PCSK9 proprotein convertase subtilisin kexin type 9, OCT optical coherence tomography, ACS acute coronary syndrome